These early studies appear to indicate that PI3K pathway inhibition confers dysfunctional HR repair, which sensitise tumours to PARPi; and is being further evaluated against chemotherapy in platinum-resistant/refractor ovarian cancer without germline BRCA1/2 mutation in the EPIK-O trial (NCT04729387). The gene discussed is BRCA1; the disease is neoplasm.